Back
Incyte Corporation (INCY)
BiotechnologyINCY · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$129.73
+1.36%Weekly undervalued picks (like INCY)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$6.41
ROE
30.8%
Gross margin
52.8%
Debt/Equity
0.70x
Revenue growth
20.9%
Incyte Corporation — company intelligence
Earnings surprises
Q2 2026$3.09 vs $2.14 est+44.1%
Q1 2026$1.81 vs $1.40 est+29.4%
Q4 2025$1.80 vs $1.97 est-8.5%
Q3 2025$2.26 vs $1.69 est+33.7%
Analyst consensus · 33 analysts
17 Buy16 Hold0 Sell
Updated Aug 13, 2026
Insider activity · 90 days
43 buys23 sellsnet +524,053 shares
Mayes Patrick Aother 6,055 · Aug 3, 2026
Mayes Patrick ASell 6,171 · Jul 31, 2026
Mayes Patrick ASell 5,332 · Jul 31, 2026
Recent SEC filings
4 — Insider transaction reportAug 14, 2026
4 — Insider transaction reportAug 7, 2026
4 — Insider transaction reportAug 7, 2026
Latest news
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors — SeekingAlpha · 3d ago
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years — Benzinga · 5d ago
Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152 — Benzinga · 5d ago
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target — Benzinga · 6d ago
7 Growth Stocks Holding Up in a Tough Market — Yahoo · 6d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like INCY)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.